* Alpine Immune Sciences Inc reported a quarterly adjusted loss of 28 cents per share for the quarter ended in January, identical to the same quarter last year. The mean expectation of seven analysts for the quarter was for a loss of 41 cents per share. Wall Street expected results to range from -51 cents to -29 cents per share.
* Revenue fell 25.1% to $7.03 million from a year ago; analysts expected $3.52 million.
* Alpine Immune Sciences Inc's reported EPS for the quarter was a loss of 28 cents.
* The company reported a quarterly loss of $17.92 million.
* Alpine Immune Sciences Inc shares had risen by 63.2% this quarter and gained 239.5% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 15.7% in the last three months.
* In the last 30 days, there have been no negative revisions of earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Alpine Immune Sciences Inc is $65.00 This summary was machine generated from LSEG data May 9 at 09:35 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.41 -0.28 Beat
Dec. 31 2023 -0.34 0.12 Beat
Sep. 30 2023 -0.33 -0.24 Beat
Jun. 30 2023 -0.37 -0.27 Beat
Comments